Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 4

Conditions

Recurrence 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 166Rituximab 153Specimen Handling 111Biopsy 89Magnetic Resonance Spectroscopy 87Vincristine 85Doxorubicin 79Prednisone 78fludarabine 68venetoclax 65obinutuzumab 60ibrutinib 54Lenalidomide 53Dexamethasone 53Cytarabine 47Methotrexate 44acalabrutinib 42Etoposide 41CT-P10 39blinatumomab 38Bendamustine Hydrochloride 34fludarabine phosphate 33prednylidene 32Gemcitabine 32deltacortene 31Calcium Dobesilate 30zanubrutinib 29pembrolizumab 29glofitamab 27Nivolumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lisaftoclax × Lymphoid × 90 days × Clear all
NCT07601607 2026-05-22

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 1/2 Not yet recruiting
51 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07428486 2026-05-07

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03913949 2026-05-01

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
74 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05147467 2026-03-27

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Ascentage Pharma Group Inc.

Phase 2 Recruiting
75 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡